The relationship between IGF2R and endosomal uptake provides an avenue for exogenous ARSB-initiated intracellular effects, as evident in the treatment of Mucopolysaccharidosis VI by replacement therapy with exogenous ARSB (58). The gene discussed is ARSB; the disease is mucopolysaccharidosis type 6.